ORGANIZATION
EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has released a comparative analysis of biopharmaceutical strategies across 10 countries, describing Japan as a “cautionary tale” where multiple policy factors have eroded the market’s international attractiveness. The report analyzes pharmaceutical…
To read the full story
Related Article
ORGANIZATION
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Generic Use Rate Hits 90% for First Time in October-December: JGA
April 7, 2026
- JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





